1018-00009 · Client 1018 · Strategy

research-memo-correlative-adjustments.docx DOCUMENT M&A / Corporate

163 / 176 ← → ✕

CALDERWOOD & HARKNESS LLP PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT

This memorandum is protected by the attorney-client privilege and constitutes attorney work product prepared in anticipation of litigation. It is not to be disclosed to any person or entity outside the attorney-client relationship without the prior written authorization of Calderwood & Harkness LLP.

MEMORANDUM

TO: Leonard Cross, Responsible Partner Garrett Simmons, Lead Associate

FROM: Leila Nazari, Working Associate

DATE: October 25, 2023

RE: Availability and Mechanics of Correlative Adjustments Under Treas. Reg. § 1.482-1(g) — Penterra Pharmaceuticals Corp. IRS Examination Defense

Matter No.: 1018-00009

Client: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)

Tax Years Under Examination: 2017, 2018, 2019, 2020

IRS Examination: LB&I-NE-TP-2022-00641

Right-click to update Table of Contents

I. Executive Summary

This memorandum analyzes the availability and mechanics of correlative adjustments under Treasury Regulation § 1.482-1(g) to prevent the double-counting of income arising from the Internal Revenue Service's concurrent proposed adjustments to (1) Penterra Pharmaceuticals Corp.'s ("PPC") cost-sharing arrangement ("CSA") with Penterra Biopharma International DAC ("PBI"), an Irish Designated Activity Company, and (2) the legacy intellectual property royalty rate between PPC and PBI. Both sets of adjustments operate on the same controlled group and, in significant measure, on the same underlying pool of PBI income. Unless properly reconciled through correlative allocations, the aggregate effect of both adjustments overstates PPC's arm's-length income and results in a net § 482 allocation that exceeds what the statute authorizes.

On October 12, 2023, the IRS issued a Notice of Proposed Adjustment ("NOPA") proposing total adjustments of $380.40 million across Tax Years 2017 through 2020. The NOPA comprises two principal components: (a) $235.01 million in CSA cost-sharing adjustments, reflecting the IRS's position that PBI's cost-sharing percentages should have been 8 to 12 percentage points higher than those reflected on PPC's returns; and (b) $188.04 million in royalty rate adjustments, reflecting the IRS's position that the legacy IP royalty rate should have been 11.0% of net sales rather than the 4.5% rate applied by the parties. To its credit, the examination team recognized a portion of the overlap and allowed a correlative offset of $42.65 million to avoid double-counting between the two adjustments, yielding the net proposed adjustment of $380.40 million.

This memorandum reaches three principal conclusions:

First, the $42.65 million correlative offset recognized by the examination team is both legally required and factually well-grounded. Treasury Regulation § 1.482-1(g)(1) mandates correlative allocations whenever the IRS makes a § 482 adjustment affecting a controlled group, and § 1.482-1(g)(2) further requires that the combined effect of multiple simultaneous adjustments be reconciled to produce an aggregate allocation consistent with the arm's-length standard—not more. The offset reflects the examination team's acknowledgment that a portion of the income captured by the royalty rate adjustment was already implicitly captured by the CSA cost-sharing adjustment.

Second, PPC has strong arguments that the $42.65 million offset understates the true economic overlap between the two adjustments. If the IRS's proposed 11.0% royalty rate is taken as correct, PBI's residual profits from legacy product lines would be significantly lower, which should proportionally reduce PBI's share of reasonably anticipated benefits ("RAB") and thus its required cost-sharing percentage under the CSA. The resulting feedback effect would reduce the CSA adjustment by more than the $42.65 million the examination team recognized. Preliminary sensitivity analyses performed by Dr. Helena Vasquez and Dr. Rohan Chakrabarti at Whitmore Valuation Group LLC suggest that a properly computed correlative offset could be materially larger—potentially in the range of $65 million to $90 million depending on the assumptions employed.

Third, the internal inconsistency inherent in the IRS's dual-adjustment position represents a significant hazard-of-litigation factor for IRS Appeals and, if necessary, for litigation in the United States Tax Court. The IRS cannot simultaneously maintain that PBI's cost-sharing ratio should be substantially higher (reflecting greater anticipated benefits) and that PBI's legacy IP royalty should be substantially higher (reducing PBI's residual profitability and, by extension, its anticipated benefits) without confronting the tension between these positions. This inconsistency should be featured prominently in PPC's Formal Protest, the filing deadline for which is December 22, 2023.

The correlative adjustment argument is independent of, and additive to, PPC's substantive defenses on the merits of the royalty rate (supported by a comparable uncontrolled transaction analysis identifying 14 comparables with an interquartile range of 3.1% to 6.8% and a median of 4.4%) and the CSA cost-sharing methodologies. Incorporation of this argument into the Formal Protest, presentation at IRS Appeals, and use in settlement negotiations are addressed in Section VII below.

II. Factual Background

A. PPC's Intercompany IP Structure

Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA, with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company whose therapeutic focus areas include oncology, immunology, and rare-disease therapeutics. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC serves as the U.S. parent of a global group of affiliated entities and is the original developer and owner of the group's pharmaceutical intellectual property portfolio.

Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized under the laws of Ireland, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI functions as the group's intellectual property holding company and principal for commercial operations outside the Americas. PBI is tax resident in Ireland and subject to Irish corporation tax on its worldwide income. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. By the end of 2020, PBI employed approximately 185 individuals in Ireland, including commercial, medical affairs, regulatory, and administrative personnel engaged in the management and exploitation of the licensed IP portfolio.

PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is treated as a disregarded entity for U.S. federal income tax purposes under Treasury Regulation § 301.7701-3 and the entity classification election filed by PPC. PHL is, in turn, 100% owned by PPC. As a consequence of PHL's disregarded status, PBI's activities are attributed directly to PPC for purposes of the U.S. international tax provisions, including Subpart F, GILTI, and BEAT, subject to the check-the-box election treating PBI itself as a separate corporation for U.S. tax purposes.

Additionally, Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates as a contract manufacturer under a cost-plus transfer pricing arrangement with PBI, receiving cost plus a markup of 8% for manufacturing services performed on behalf of PBI. PMI employed approximately 620 individuals during the tax years under examination. PMI's activities include active pharmaceutical ingredient synthesis, formulation, fill-finish, and quality control testing for products destined for non-Americas markets.

The intercompany IP structure at issue in this examination involves two principal categories of intercompany transactions between PPC and PBI: (1) the cost-sharing arrangement governing jointly developed IP, and (2) the legacy IP royalty arrangement governing pre-existing compounds. These are described in Sections II.B and II.C below.

B. The Cost-Sharing Arrangement

Effective July 1, 2012, PPC and PBI entered into a Qualified Cost Sharing Arrangement (the "CSA") governed by Treasury Regulation § 1.482-7. Under the CSA, PBI acquired the rights to develop and exploit PPC's pharmaceutical intellectual property outside the Americas (defined as the United States, Canada, Mexico, Central America, South America, and the Caribbean) in exchange for two categories of consideration:

First, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC at the inception of the CSA. The PCT payment compensated PPC for making available to the CSA the existing platform of pharmaceutical IP—including patents, trade secrets, clinical data, regulatory filings, and know-how—that PPC had developed prior to the CSA's effective date and that would serve as the foundation for future joint development activities. The PCT payment was determined using a discounted cash flow methodology, as required under Treasury Regulation § 1.482-7(g).

Second, PBI has made, and continues to make, ongoing cost-sharing payments to PPC. These payments represent PBI's share of the intangible development costs ("Coss") incurred by PPC in conducting research and development activities that benefit both parties to the CSA. PBI's share is determined annually based on its reasonably anticipated benefits ("RAB") from the CSA, expressed as a percentage of total RAB. The RAB methodology employed by PPC and PBI uses projected sales-based profit metrics, consistent with the regulatory framework under § 1.482-7(e)(2)(ii).

PBI's cost-sharing percentages for the tax years under examination, and the corresponding dollar amounts, were as follows:

The upward trend in PBI's cost-sharing percentages over the 2017–2020 period reflects PBI's growing share of anticipated benefits as several CSA-covered compounds received regulatory approvals and achieved commercial launch in non-Americas markets. The RAB projections underlying these percentages were updated annually by PPC's transfer pricing team in consultation with independent economists, and the methodology and results were documented in PPC's contemporaneous transfer pricing documentation for each tax year.

C. The Legacy IP Royalty Arrangement

Separate and apart from the CSA, PBI holds a license from PPC to exploit certain legacy pharmaceutical compounds in the non-Americas territory. These legacy compounds—principally those with patent filings and initial clinical development predating the July 1, 2012 effective date of the CSA—were carved out of the CSA and instead made available to PBI under a standalone intercompany licensing agreement. Under this license, PBI pays PPC a royalty of 4.5% of net sales generated by the legacy compounds in the non-Americas territory.

The 4.5% royalty rate was established by PPC at the time of the initial licensing arrangement based on a comparable uncontrolled transaction ("CUT") analysis identifying arm's-length royalty rates for licenses of pharmaceutical compounds at a comparable stage of development and with comparable risk profiles. PPC's contemporaneous transfer pricing documentation describes the CUT analysis and its conclusions in detail.

The legacy compound non-Americas net sales and corresponding royalties for the tax years under examination were as follows:

The declining trajectory of legacy compound net sales reflects the natural lifecycle of these products as they faced generic competition, patent expiration, and declining market share in various non-Americas jurisdictions. This decline is relevant to the IRS's royalty rate adjustment and to the correlative offset calculation, as discussed below.

D. The IRS's Proposed Adjustments (NOPA, October 12, 2023)

On October 12, 2023, the IRS examination team issued a Notice of Proposed Adjustment encompassing two categories of § 482 adjustments for Tax Years 2017 through 2020, together with a partial correlative offset and a proposed penalty. Each component is described below.

1. CSA Cost-Sharing Adjustments ($235.01 Million Total)

The IRS proposed increasing PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points per year, on the basis that PPC's RAB methodology underestimated PBI's share of anticipated benefits from the jointly developed IP. The IRS's proposed adjustments are as follows:

The IRS's position rests primarily on two contentions: (a) that PPC's RAB projections underestimated the growth potential of the non-Americas markets for CSA-covered compounds, and (b) that PPC failed to adequately account for the value of pre-existing intangibles (beyond the PCT payment) that continued to benefit PBI's commercial operations.

2. Royalty Rate Adjustments ($188.04 Million Total)

Separately, the IRS proposed increasing the legacy IP royalty rate from 4.5% of net sales to 11.0% of net sales, contending that PPC's CUT analysis was deficient and that the arm's-length royalty rate for the licensed legacy compounds should be materially higher. The year-by-year adjustments are as follows:

The IRS's royalty rate adjustment is based on the examination team's application of a CUT analysis using comparables that PPC contends are materially dissimilar (as discussed in separate memoranda addressing the substantive royalty rate defense).

3. Correlative Offset Allowed by Examination ($42.65 Million)

Recognizing the potential for double-counting, the examination team allowed a correlative offset of $42.65 million as a reduction to the combined proposed adjustment. This offset was computed by the IRS's economist, Dr. Alan Washburne, and reviewed by IRS Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi. Revenue Agent Patricia Dunleavy and Supervisory Revenue Agent Gerald Meskill approved the inclusion of the offset in the final NOPA.

4. Net Proposed Adjustment

The net proposed adjustment is calculated as follows:

5. Proposed Penalty

The NOPA proposes a penalty under IRC § 6662(e) for substantial valuation misstatement. The penalty is calculated at 20% of the underpayment attributable to the net § 482 allocation:

$380.40 million × 21% (corporate tax rate) × 20% (penalty rate) ≈ $15.98 million

The penalty calculation applies the 21% corporate rate for TY 2018–2020; for TY 2017, a blended rate reflecting the pre-TCJA 35% rate for the portion of the year before December 22, 2017, and the post-TCJA 21% rate thereafter would be technically applicable, though the NOPA appears to have used 21% across all years as a simplification.

E. The Overlap / Double-Counting Problem

The central issue addressed in this memorandum is the economic and legal overlap between the CSA cost-sharing adjustment and the royalty rate adjustment, which creates a double-counting problem that the correlative offset is intended to address.

The CSA cost-sharing ratio is driven by RAB projections, which measure each party's anticipated benefits from the jointly developed IP. The RAB calculation is forward-looking and depends on assumptions about the future profitability of each participant's exploitation of the CSA-covered intangibles. Critically, while the CSA and legacy royalty arrangements are nominally separate transactions, they operate on the same entity—PBI—and PBI's overall financial profile, including its profitability from all sources, can influence the economic analysis underlying the RAB determination.

When the IRS simultaneously (a) increases the cost-sharing ratio (thereby allocating more R&D costs to PBI and reducing PBI's net income from CSA-covered activities) and (b) increases the royalty rate on legacy IP (thereby allocating more royalty income to PPC and further reducing PBI's net income from legacy product lines), both adjustments seek to increase PPC's U.S.-source income from the same overall intercompany relationship with PBI. To the extent both adjustments capture overlapping portions of PBI's income—that is, the higher royalty reduces PBI's residual profit, which in turn would already be reflected in a properly adjusted RAB calculation—a correlative offset is necessary to prevent overstatement of PPC's allocable income.

More specifically, the mechanism of overlap operates as follows: If PBI is required to pay a higher royalty rate (11.0% rather than 4.5%) on legacy compound net sales, PBI's aggregate profitability declines. Under the RAB methodology, PBI's anticipated benefits from the CSA are measured, in part, by reference to PBI's projected income. A lower overall profitability for PBI would translate into a lower RAB share for PBI, which would in turn reduce PBI's required cost-sharing percentage. The IRS's proposed CSA adjustment, however, increases PBI's cost-sharing percentage without fully accounting for the profit-reducing effect of the simultaneously proposed royalty rate increase. The result is an aggregate adjustment that attributes more income to PPC than would be the case if both adjustments were computed on a consistent basis.

The $42.65 million offset represents the examination team's partial recognition of this problem. As discussed in Section IV below, PPC has grounds to argue that the offset is insufficient and that a properly computed correlative adjustment would be materially larger.

III. Legal Framework: Treas. Reg. § 1.482-1(g) — Correlative Allocations

A. Statutory Authority — IRC § 482

Internal Revenue Code § 482 provides the Secretary of the Treasury with broad authority to reallocate income, deductions, credits, and allowances among commonly controlled entities in order to prevent the evasion of taxes or to clearly reflect the income of such entities. The statute reads, in relevant part:

"In any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, the Secretary may distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses, if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses."

The implementing regulations under § 482 establish the arm's-length standard as the governing principle for evaluating controlled transactions. Treasury Regulation § 1.482-1(b)(1) provides that a controlled transaction meets the arm's-length standard if the results of the transaction are consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. This standard is the touchstone against which all § 482 adjustments must be measured. An adjustment that exceeds the arm's-length amount is as impermissible as one that falls short of it; the statute authorizes allocation of the arm's-length amount, and no more.

The best method rule, set forth in Treasury Regulation § 1.482-1(c), requires the selection of the pricing method that provides the most reliable measure of an arm's-length result under the facts and circumstances of each case. The best method rule is relevant here because the IRS's simultaneous application of separate methods to the CSA and royalty transactions must yield results that are collectively consistent with arm's-length outcomes when viewed in the aggregate.

B. Treas. Reg. § 1.482-1(g)(1) — In General

Treasury Regulation § 1.482-1(g)(1) establishes the fundamental principle of correlative allocations. The regulation provides:

"When the district director makes an allocation under section 482, appropriate correlative allocations will be made with respect to any other member of the group affected by the allocation."

The purpose of the correlative allocation requirement is straightforward: a § 482 allocation that increases the income of one member of a controlled group necessarily implies a corresponding decrease in the income of another member of the group. The correlative allocation ensures that the total income of the controlled group is neither overstated nor understated—i.e., that the § 482 reallocation is a zero-sum exercise within the group. Without a correlative adjustment, an upward allocation to one entity would increase the aggregate income of the group beyond the arm's-length amount, resulting in double taxation of a portion of the group's income.

The correlative allocation is made automatically as a matter of law. It is not discretionary. The regulation uses the mandatory term "will be made," not "may be made." The IRS is obligated to make appropriate correlative allocations whenever it exercises its authority under § 482, and the taxpayer is entitled to the benefit of such allocations. This principle has been consistently upheld in the case law and is foundational to the administration of the transfer pricing rules.

C. Treas. Reg. § 1.482-1(g)(2) — Correlative Allocations Where More Than One Adjustment

When the IRS makes multiple § 482 allocations affecting the same controlled group—as it has done here, with the CSA adjustment and the royalty adjustment both affecting PPC and PBI—Treasury Regulation § 1.482-1(g)(2) requires that the combined effect of all allocations be consistent with the arm's-length standard. This provision operates as a check on the IRS's authority: the IRS may not make separate adjustments that, taken individually, might each be defensible, but that in the aggregate exceed the arm's-length result for the controlled group.

The regulation reflects a recognition that controlled transactions do not exist in isolation. When two intercompany transactions involve the same parties and draw upon the same pool of the foreign affiliate's income, adjustments to those transactions can interact in ways that produce overlapping income inclusions. The correlative allocation mechanism under § 1.482-1(g)(2) requires that these interactions be identified and reconciled so that the aggregate income allocated to the U.S. taxpayer equals the arm's-length amount—not a higher amount that results from treating each transaction as if it existed independently.

This requirement implicates the broader debate between the "aggregate" and "transactional" approaches to § 482 adjustments. Under a purely transactional approach, each controlled transaction is analyzed separately, and the arm's-length price for each transaction is determined independently. Under an aggregate approach, the combined effect of all controlled transactions between the parties is evaluated to determine whether the overall results are consistent with arm's-length outcomes. The regulations generally adopt a transactional approach, see Treas. Reg. § 1.482-1(d)(3)(ii), but the correlative allocation provisions of § 1.482-1(g) serve as a critical safety valve, ensuring that the transactional approach does not produce aggregate results that exceed the arm's-length standard. Where two transactional adjustments interact to produce overlapping income inclusions, the regulations mandate a correlative reconciliation.

D. Treas. Reg. § 1.482-1(g)(3) — Procedures for Correlative Allocations

Treasury Regulation § 1.482-1(g)(3) sets forth the procedures by which the affected member of the controlled group (here, PBI) obtains the benefit of a correlative downward adjustment when the other member's income (here, PPC's income) is adjusted upward. The regulation provides that the correlative allocation is reflected on the return of the affected member for the taxable year to which the § 482 allocation relates.

In PPC's case, the procedural posture is somewhat simplified by the corporate ownership structure. PBI is owned by PHL, which is treated as a disregarded entity for U.S. federal tax purposes. PHL is, in turn, owned directly by PPC. As a result, the correlative allocation effectively operates on a consolidated or aggregated basis on PPC's U.S. return in terms of computing the net § 482 adjustment. The upward adjustment to PPC's income (reflecting higher cost-sharing payments from PBI and higher royalty income from PBI) and the correlative downward adjustment to PBI's income (reflecting PBI's lower residual profits) are both accounted for within the same U.S. tax return framework, given PBI's status as a controlled foreign corporation ("CFC") whose income flows through to PPC under the Subpart F and GILTI regimes.

It is important, however, to distinguish between two different concepts that the term "correlative allocation" can describe. The first is the mechanical correlative allocation required by § 1.482-1(g)(1)—the reduction of PBI's income to mirror PPC's increase. The second is the practical need to avoid double-counting when two adjustments apply to the same income stream. The $42.65 million offset at issue in this memorandum is an example of the latter: it is not merely a mirror-image reduction of PBI's income, but rather a reconciliation of two separate adjustments that, absent the offset, would collectively attribute more income to PPC than the arm's-length standard permits. Both concepts are grounded in the same regulatory authority—§ 1.482-1(g)—but they operate at different levels of the analysis.

E. Treas. Reg. § 1.482-1(g)(4) — Conforming Adjustments to Other Tax Items

Treasury Regulation § 1.482-1(g)(4) requires that when a § 482 allocation is made, conforming adjustments must be made to all affected tax items. The regulation recognizes that a § 482 allocation does not exist in a vacuum; it has ripple effects throughout the tax system that must be accounted for to produce a coherent result.

Specifically, the conforming adjustments may include, but are not limited to:

(a) Adjustments to withholding tax liability on royalty payments, dividends, or other intercompany payments that are increased or decreased as a result of the § 482 allocation;

(b) Adjustments to foreign tax credit computations under IRC §§ 901–909, reflecting changes in the sourcing and categorization of income;

(d) Adjustments to Subpart F income inclusions, to the extent the § 482 allocation alters the character or amount of the CFC's income that is subject to current inclusion under IRC §§ 951–964;

(e) Adjustments to tested income for purposes of the Global Intangible Low-Taxed Income ("GILTI") inclusion under IRC § 951A, applicable for TY 2018–2020; and

(f) Adjustments to the base erosion and anti-abuse tax ("BEAT") calculation under IRC § 59A, to the extent the § 482 allocation affects the amount of base erosion payments.

Each of these conforming adjustments is relevant to PPC's examination. The GILTI and BEAT implications of the proposed adjustments are discussed in Section VI.B below, and a full quantitative analysis of these interactions is being prepared in a separate memorandum. The earnings and profits and Subpart F implications are discussed in Section VI.D.

IV. Application to PPC's Examination: The $42.65 Million Correlative Offset

A. Nature of the Overlap Between CSA and Royalty Adjustments

The CSA adjustment and the royalty adjustment proposed in the NOPA create overlapping income allocations to PPC through the following mechanism:

CSA Adjustment — Reducing PBI's Post-CSA Residual Profit. The CSA adjustment increases PBI's required cost-sharing payment to PPC. By raising PBI's cost-sharing percentage (from 38.2%–42.7% to 48.2%–53.7%), the IRS requires PBI to bear a larger share of the total R&D costs. The additional cost-sharing payments flow from PBI to PPC, reducing PBI's post-CSA residual profit from the exploitation of CSA-covered IP and correspondingly increasing PPC's income. Over the four-year period, this component allocates an additional $235.01 million of income to PPC.

Royalty Adjustment — Further Reducing PBI's Profit. The royalty adjustment increases PBI's royalty payment to PPC on legacy IP from 4.5% to 11.0% of net sales. The additional royalty payments flow from PBI to PPC, reducing PBI's profit from the legacy product lines and correspondingly increasing PPC's royalty income. Over the four-year period, this component allocates an additional $188.04 million of income to PPC.

The Interaction. Both adjustments operate on PBI's income. The CSA adjustment draws from PBI's income attributable to CSA-covered IP, and the royalty adjustment draws from PBI's income attributable to legacy IP. At first blush, these might appear to be independent adjustments affecting different income streams. However, they interact through the RAB calculation that determines PBI's cost-sharing percentage under the CSA.

The RAB calculation is a forward-looking assessment of each participant's anticipated benefits from the CSA. PBI's anticipated benefits are a function of its projected profitability from the exploitation of CSA-covered IP in the non-Americas territory. While the RAB calculation is, in principle, limited to benefits attributable to the CSA-covered IP (rather than the legacy IP), the two income streams are not entirely independent. PBI's overall financial profile—including its profitability from legacy products—affects its capacity to invest in commercialization, its market presence, and its infrastructure, all of which bear on the anticipated benefits it will derive from CSA-covered products.

More importantly, the IRS's own methodology for computing the RAB shares implicitly incorporates assumptions about PBI's overall profitability. To the extent the IRS's proposed 11.0% royalty rate would, if applied, reduce PBI's aggregate income, that reduced income should, in a consistent analysis, feed back into the RAB calculation and lower PBI's share of anticipated benefits. In other words, a PBI that is paying 11.0% royalties on legacy compounds (instead of 4.5%) is a less profitable PBI, and a less profitable PBI would be expected to derive lower anticipated benefits from the CSA—which should translate into a lower, not higher, cost-sharing percentage.

The $42.65 million offset reflects the examination team's recognition that a portion of the income captured by the royalty rate adjustment was already implicitly captured by the CSA cost-sharing adjustment. Without the offset, the aggregate adjustment of $423.05 million ($235.01M + $188.04M) would attribute more income to PPC than the arm's-length result permits. The offset brings the net adjustment to $380.40 million, but as discussed in Section IV.C, PPC has grounds to argue that even this reduced amount overstates PPC's arm's-length income.

B. Calculation Mechanics of the $42.65 Million Offset

The correlative offset of $42.65 million was computed by the IRS's economist, Dr. Alan Washburne, as part of the NOPA calculations. Based on the NOPA and supporting workpapers provided by the examination team, the offset was derived as follows:

The offset addresses the extent to which higher royalty payments from PBI to PPC (reflecting the proposed 11.0% royalty rate) would, if properly reflected in the RAB calculation, reduce PBI's cost-sharing percentage—partially offsetting the proposed increase to that percentage. The offset is, in essence, a "feedback" adjustment: it reduces the CSA adjustment to account for the profit-reducing effect of the royalty adjustment on PBI's anticipated benefits.

The year-by-year allocation of the $42.65 million offset, based on the relative magnitude of the overlapping adjustments in each year, is as follows:

Several observations merit note regarding these calculations:

First, the offset is proportionally larger in earlier years (2017 and 2018), when the legacy compound net sales were higher and the royalty adjustment had a greater absolute impact on PBI's profitability. This is consistent with the economic logic underlying the offset: a larger royalty adjustment has a greater feedback effect on PBI's anticipated benefits and thus a greater impact on the RAB calculation.

Second, the examination team's workpapers indicate that the offset was computed using a partial-equilibrium approach—i.e., the feedback effect of the royalty adjustment on the RAB calculation was estimated at a single iteration rather than solved to convergence. This methodological choice may understate the true offset, as a fully iterated computation would capture second-order effects (e.g., the reduced cost-sharing percentage would itself affect PBI's profitability, which would further affect the RAB calculation).

Third, the offset was reviewed and approved by IRS Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi, and was included in the NOPA as signed by Revenue Agent Patricia Dunleavy and approved by Supervisory Revenue Agent Gerald Meskill. The fact that the IRS has already conceded the need for a correlative offset—and has quantified it at $42.65 million—is significant for PPC's position. It establishes a floor: the IRS cannot credibly argue at Appeals or in litigation that no offset is required, having already allowed one in the NOPA. The only question is whether the offset should be larger.

C. Argument That the $42.65 Million Offset Is Insufficient

PPC's position, to be developed in the Formal Protest and presented at Appeals, should argue that the $42.65 million correlative offset understates the true economic overlap between the CSA and royalty adjustments. The argument has several components:

1. The RAB Feedback Effect Is Understated. If the IRS's proposed 11.0% royalty rate is taken as correct, PBI's residual profits from legacy product lines would be significantly lower than those reflected in PPC's reported positions. The incremental royalty payments of $188.04 million over four years represent a substantial reduction in PBI's aggregate profitability. Under the RAB methodology, PBI's anticipated benefits from the CSA are a function of its projected income. A PBI that is paying $188 million more in royalties over the period is, by definition, a less profitable entity with lower anticipated benefits from the CSA. This should proportionally reduce PBI's RAB share and thus its required cost-sharing percentage—potentially by more than the 8 to 12 percentage point increase the IRS proposes.

To illustrate: if PBI's RAB share were recalculated using the IRS's proposed 11.0% royalty rate as an input (rather than the 4.5% rate reflected in PPC's returns), the resulting cost-sharing ratios for PBI would be lower than those proposed by the IRS. The magnitude of the reduction depends on the specific RAB model and assumptions employed, but preliminary modeling by Whitmore Valuation Group suggests that the cost-sharing percentages, after accounting for the royalty adjustment, would be approximately 2 to 5 percentage points lower than the IRS's proposed percentages—implying a correlative offset significantly larger than $42.65 million.

2. Sensitivity Analysis. Dr. Helena Vasquez and Dr. Rohan Chakrabarti at Whitmore Valuation Group LLC (200 Ashbury Asset Advisors, Suite 700, Boston, MA 02109) have modeled alternative offset scenarios under the Kovel arrangement (letter reference 1018-00009-KV, executed June 20, 2022) pursuant to which Whitmore performs its analysis under the protection of attorney-client privilege. Whitmore's blended billing rate is $650 per hour. Their preliminary findings indicate:

(a) If PBI's RAB is recalculated using the 11.0% royalty rate and a fully iterated convergence methodology, the correlative offset would be approximately $78.3 million — nearly double the $42.65 million allowed by the examination team.

(b) If additional feedback effects are considered (including the impact of reduced PBI profitability on PBI's market development capacity and projected sales growth), the offset could reach approximately $91.6 million.

(c) Under a conservative midpoint estimate, the correlative offset should be no less than $65 million, representing a $22.35 million increase over the examination team's figure.

3. Internal Inconsistency as a Hazard-of-Litigation Factor. The internal inconsistency in the IRS's position is a significant vulnerability. The IRS cannot simultaneously maintain that PBI's cost-sharing ratio should be substantially higher (reflecting greater anticipated benefits from the CSA) and that PBI's legacy IP royalty should be substantially higher (reducing PBI's residual profitability and, by extension, its capacity to generate anticipated benefits from any source). These two positions are in tension: one posits a more profitable PBI (higher RAB share), while the other posits a less profitable PBI (higher royalty payments). At Appeals, this inconsistency can be highlighted as evidence that the IRS's aggregate proposed adjustment exceeds the arm's-length result, strengthening PPC's case for a larger correlative offset and a lower net adjustment.

4. Burden of Proof Considerations. Under IRC § 7491(a), the burden of proof on a factual issue shifts to the IRS in a Tax Court proceeding if the taxpayer has maintained adequate records and has cooperated with the IRS's reasonable requests for information. PPC has maintained contemporaneous transfer pricing documentation for each year and has cooperated fully with the examination. If the case proceeds to litigation, PPC can argue that the IRS bears the burden of proving that its $42.65 million offset is the correct amount, and that PPC's evidence (including the Whitmore sensitivity analysis) demonstrates that the correct amount is higher.

V. Case Law Supporting Correlative Adjustments

A. General Principles

The requirement of correlative adjustments in § 482 cases has been recognized and enforced by the Tax Court and the federal courts of appeals in a consistent line of precedent. The overarching principle is that IRC § 482 authorizes the IRS to allocate the arm's-length amount of income—and no more. An allocation that, in the aggregate, exceeds the arm's-length result for the controlled group violates the statute, regardless of whether the individual components of the allocation might be defensible in isolation.

This principle is a direct corollary of the arm's-length standard itself. Treasury Regulation § 1.482-1(b)(1) requires that controlled transactions produce results consistent with those that uncontrolled parties would achieve. If two uncontrolled parties entered into both a cost-sharing arrangement and a separate licensing agreement, the terms of each transaction would reflect the parties' overall economic relationship. An uncontrolled licensee paying a higher royalty rate would negotiate a lower cost-sharing percentage (or a lower PCT payment) to compensate, and vice versa. The correlative adjustment ensures that the IRS's allocations replicate this market dynamic rather than ignoring it.

The courts have also recognized that § 482 is a tool for "clearly reflecting income"—not for maximizing the U.S. fisc's revenue. The Supreme Court in Commissioner v. First Security Bank of Utah, N.A., 405 U.S. 394 (1972), emphasized that § 482 is to be applied in a manner that produces a fair reflection of income, not a punitive one. The corollary is that the IRS may not use § 482 to "whipsaw" a taxpayer by making inconsistent adjustments that collectively exceed the arm's-length result. See also Crowne Albany Industries v. Commissioner, 856 F.2d 855 (7th Cir. 1988) (discussing the purpose and limits of § 482 adjustments).

B. Relevant Precedent

Several lines of precedent are relevant to PPC's correlative adjustment argument:

1. Multiple Intercompany Transactions and the Anti-Whipsaw Principle. Courts have recognized that when the IRS makes adjustments to multiple intercompany transactions between the same controlled parties, the adjustments must be internally consistent. The IRS may not, for example, increase the price of one intercompany transaction on the ground that the U.S. entity's contribution of value was higher, while simultaneously increasing the price of a different intercompany transaction on the ground that the U.S. entity's contribution of value to the same overall relationship was also higher, if the two adjustments together attribute more value to the U.S. entity than the entity actually contributed.

In Bausch & Lomb, Inc. v. Commissioner, 92 T.C. 525 (1989), aff'd, 933 F.2d 1084 (2d Cir. 1991), the Tax Court examined the IRS's authority to make § 482 adjustments and recognized that the arm's-length standard imposes a ceiling on the aggregate adjustment. While the specific facts of Bausch & Lomb involved a different configuration of intercompany transactions, the principle is directly applicable: the IRS's authority under § 482 is bounded by the arm's-length result, and correlative adjustments are the mechanism by which that boundary is enforced when multiple adjustments are made.

2. CSA-Specific Precedent. The interaction between CSA adjustments and other § 482 adjustments has been considered in the modern cost-sharing litigation. In Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), remanded to T.C., T.C. Memo. 2022-84, the Eighth Circuit addressed the IRS's proposed § 482 adjustments to intercompany royalty and other transfer pricing arrangements involving Harborview Corporation's Puerto Rico operations. While the Harborview Corporation case primarily concerned the appropriate method for valuing intercompany IP transfers (and the Tax Court on remand applied a modified CUT analysis), the case is instructive for PPC's purposes because it illustrates the principle that the IRS's proposed adjustments must be internally consistent and that the Tax Court has authority to determine the correct arm's-length result even if it differs from both the taxpayer's and the IRS's positions.

In Altera Corp. v. Commissioner, 145 T.C. 91 (2015), rev'd, 941 F.3d 1200 (9th Cir. 2019), cert. denied, 141 S. Ct. 131 (2020), the Ninth Circuit addressed the validity of Treasury Regulation § 1.482-7(d)(2) (the stock-based compensation cost-sharing regulation) and its consistency with the arm's-length standard. Although Altera does not directly address correlative adjustments, the decision's emphasis on the arm's-length standard as the governing constraint on § 482 regulations supports PPC's argument that the aggregate effect of the IRS's adjustments must conform to the arm's-length standard—and that a correlative offset is the mechanism for achieving that conformity.

3. Consistency Requirement and the IRS's Obligation to Reconcile. The Tax Court has consistently held that the IRS bears the burden of demonstrating that its proposed § 482 adjustments clearly reflect income. See, e.g., Sundstrand Corp. v. Commissioner, 96 T.C. 226, 353 (1991) (holding that the IRS's determinations under § 482 are entitled to a presumption of correctness, but that the taxpayer may rebut this presumption by showing that the adjustments do not clearly reflect income). When the taxpayer demonstrates that two simultaneous adjustments produce overlapping income inclusions, the IRS's presumption of correctness as to the aggregate adjustment is weakened, and the IRS must justify the combined amount.

4. OECD Transfer Pricing Guidelines as Persuasive Authority. The OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017, as updated in 2022) serve as persuasive (though not binding) authority in U.S. transfer pricing cases. The Guidelines support the principle that correlative adjustments are necessary to avoid double taxation when multiple transfer pricing adjustments are made to transactions between the same controlled parties.

Chapter I of the Guidelines (Arm's Length Principle) emphasizes at Paragraph 1.6 that the arm's-length principle should be applied consistently across all controlled transactions, and that adjustments to one transaction may need to be reconciled with adjustments to other transactions involving the same parties. Chapter VIII (Cost Contribution Arrangements) addresses the interaction between cost-sharing adjustments and other transfer pricing adjustments at Paragraphs 8.39–8.44, noting that adjustments to a CCA participant's cost-sharing percentage must be consistent with the overall allocation of income between the participants.

The 2022 revisions to the OECD Guidelines further reinforce the principle that correlative adjustments are necessary to prevent double taxation, particularly in the context of simultaneous adjustments by the same tax administration. While the OECD Guidelines' treatment of corresponding adjustments (Chapter IV) primarily addresses bilateral adjustments between two countries, the underlying principle—that adjustments should not result in an aggregate allocation exceeding the arm's-length amount—is equally applicable to multiple adjustments by a single tax authority affecting the same controlled group.

VI. Interaction with Other Provisions

A. IRC § 367(d) — Outbound IP Transfer

A separate memorandum analyzes the risk that the IRS may seek to recharacterize the CSA (or the PCT payment component thereof) as an outbound transfer of intangible property subject to IRC § 367(d). Under § 367(d), a U.S. person who transfers intangible property to a foreign corporation in a § 351 exchange or a § 361 reorganization is treated as having sold the property in exchange for annual payments contingent on the productivity, use, or disposition of the intangible—i.e., an imputed royalty stream.

If the IRS were to recharacterize the CSA as a § 367(d) outbound transfer, correlative adjustments would still be required under Treasury Regulation § 1.482-1(g) to avoid double-counting with any royalty adjustments. Specifically:

(a) The § 367(d) annual inclusion mechanism would require PPC to include in income an amount reflecting the arm's-length royalty for the transferred intangibles. This amount would need to be reconciled with the royalty income already being allocated to PPC under the legacy IP royalty adjustment. If both the § 367(d) inclusion and the royalty adjustment captured overlapping value attributable to the same intangible property, a correlative offset would be mandatory.

(b) Similarly, the § 367(d) inclusion would need to be reconciled with the CSA cost-sharing adjustment. To the extent the cost-sharing adjustment already captures a portion of the value that would otherwise be allocated through a § 367(d) inclusion, the two cannot both apply to their full amounts without exceeding the arm's-length result.

While the § 367(d) recharacterization risk is addressed in a separate memorandum, the correlative adjustment analysis set forth herein applies with equal force to any alternative characterization of the CSA that the IRS might advance.

B. GILTI (IRC § 951A) and BEAT (IRC § 59A) Implications

For Tax Years 2018 through 2020 (the post-Tax Cuts and Jobs Act period, during which the federal corporate tax rate is 21%), the correlative adjustment has significant implications for PPC's Global Intangible Low-Taxed Income ("GILTI") inclusion under IRC § 951A and its base erosion and anti-abuse tax ("BEAT") liability under IRC § 59A.

GILTI Implications. PBI is a controlled foreign corporation ("CFC") whose tested income is subject to the GILTI regime. The correlative adjustment affects PBI's tested income as follows: A larger correlative offset reduces PPC's § 482 adjustment (reducing PPC's directly allocated income) but correspondingly increases PBI's tested income (because PBI retains more of its profits). To the extent PBI's increased tested income flows through to PPC as a GILTI inclusion, the net effect of a larger correlative offset on PPC's total U.S. tax liability is partially offset by the increased GILTI inclusion.

However, the GILTI inclusion is not dollar-for-dollar: the GILTI regime provides for a 50% deduction under IRC § 250(a)(1)(B) (reducing the effective rate on GILTI income to approximately 10.5% before considering foreign tax credits), and PPC may be entitled to foreign tax credits under IRC § 960 for Irish taxes paid by PBI on the additional tested income. As a result, a dollar of income that shifts from direct § 482 adjustment (taxed at 21%) to GILTI inclusion (effectively taxed at approximately 10.5%, less foreign tax credits) produces a net tax saving to PPC. This asymmetry further supports PPC's argument for a larger correlative offset, as the net tax cost of the offset is lower than the IRS's calculation might suggest.

BEAT Implications. The royalty adjustment increases the amount of intercompany royalty payments from PBI to PPC. Under the BEAT regime, base erosion payments to foreign related parties are added back to the modified taxable income base for purposes of computing the BEAT liability. To the extent the royalty adjustment increases the characterization of amounts paid by PBI to PPC as "royalties" (an item that could, in certain analytical frameworks, be viewed as a base erosion payment from the reverse perspective), the interaction with the BEAT calculation must be carefully modeled. In PPC's case, because the royalty flows from the foreign entity (PBI) to the domestic parent (PPC), the BEAT implications primarily affect the computation of PPC's regular tax liability rather than creating a BEAT exposure per se. However, the conforming adjustment to PBI's earnings and profits may have indirect BEAT consequences that must be quantified.

These GILTI and BEAT interactions must be modeled quantitatively to determine the net effect on PPC's total U.S. tax liability. A detailed quantitative analysis is being prepared in a separate memorandum.

TY 2017 Considerations. Tax Year 2017 was subject to the pre-TCJA 35% corporate tax rate for the majority of the year (January 1 through December 21, 2017), with the post-TCJA 21% rate applying for the period from December 22 through December 31, 2017. The GILTI and BEAT provisions were not yet in effect for TY 2017, and accordingly, the correlative adjustment analysis for TY 2017 is simpler: the § 482 adjustment is taxed at the blended TY 2017 rate (approximately 34% for a calendar-year taxpayer) without the offsetting GILTI/BEAT considerations.

C. Competent Authority / Mutual Agreement Procedure

If the § 482 adjustments result in economic double taxation—that is, if the upward adjustment to PPC's U.S. income is not matched by a corresponding downward adjustment to PBI's Irish income—PPC may seek relief under the income tax treaty between the United States and Ireland (Convention between the Government of the United States of America and the Government of Ireland for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital Gains, signed November 28, 1997, as amended by the 1999 Protocol). Article 25 of the treaty provides for a mutual agreement procedure ("MAP") through which the competent authorities of the two countries may seek to resolve cases of taxation not in accordance with the treaty.

The correlative adjustment under Treasury Regulation § 1.482-1(g) is a domestic mechanism: it reconciles the U.S. tax treatment of the controlled transactions but does not, by itself, produce a corresponding adjustment on the Irish side. To the extent Ireland does not reduce PBI's Irish taxable income to reflect the U.S. § 482 adjustments, PPC faces the prospect of double taxation of the same income—once in the United States (through the § 482 adjustment) and once in Ireland (through PBI's Irish tax return, which continues to reflect the original intercompany pricing).

A competent authority request / MAP filing would require coordination between PPC's U.S. counsel and PBI's Irish tax advisors. PBI is advised on Irish tax matters by Thornbury & Keogh, led by Ciarán Thornbury, at 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland. Any MAP filing would need to be prepared in coordination with Thornbury & Keogh to ensure that the Irish competent authority is presented with a consistent factual and legal narrative.

The timing of a MAP filing depends on the resolution of the U.S. examination. Revenue Procedure 2015-40 provides the procedural framework for requesting competent authority assistance, including the requirement that a request generally be made within a specified period after the IRS proposes its adjustments. PPC should be mindful of this deadline and prepared to file a protective MAP request if the examination is not resolved at Appeals within a reasonable timeframe.

D. Earnings and Profits / Subpart F

A § 482 adjustment to PPC's income triggers conforming adjustments to PBI's earnings and profits under Treasury Regulation § 1.482-1(g)(4) and IRC § 312. Specifically:

(a) The upward adjustment to PPC's income (reflecting higher cost-sharing payments and higher royalties from PBI) results in a corresponding downward adjustment to PBI's current earnings and profits for the relevant tax years. This reduction in PBI's E&P may affect PBI's accumulated E&P balance, which in turn affects the characterization of any distributions from PBI (or deemed distributions, such as those arising under IRC § 956).

(b) To the extent PBI has Subpart F income under IRC § 952 (e.g., foreign base company sales income or foreign personal holding company income from royalty payments to PPC), the § 482 adjustment may alter the amount of Subpart F income includible in PPC's gross income. Specifically, if the royalty rate adjustment increases the amount of PBI's royalty payments to PPC, PBI's deductible expense increases, reducing PBI's net income and potentially reducing the amount of Subpart F income.

(c) The conforming adjustment to PBI's E&P also affects the computation of previously taxed earnings and profits ("PTEP") under IRC § 959, which in turn affects the treatment of future distributions from PBI to PHL (and, by extension, to PPC). An increase in the § 482 adjustment to PPC's income may generate additional PTEP that would shield future distributions from further taxation.

(d) Additionally, the withholding tax implications must be considered. Under Article 12 of the U.S.-Ireland income tax treaty, royalties paid by PBI (an Irish entity) to PPC (a U.S. entity) are generally exempt from Irish withholding tax, provided the beneficial owner is a resident of the other contracting state and holds a specified ownership interest. To the extent the § 482 adjustment increases the deemed royalty payment from PBI to PPC, the withholding tax analysis must be confirmed, including verification that the treaty exemption continues to apply to the increased amount.

These E&P, Subpart F, and withholding tax implications are being quantified as part of the comprehensive tax impact analysis and will be addressed in a separate memorandum.

VII. Strategic Recommendations for Formal Protest and Appeals

A. Incorporating the Correlative Adjustment Argument into the Protest

The Formal Protest, which must be filed by December 22, 2023, should include a dedicated section arguing that the $42.65 million correlative offset recognized in the NOPA is both (a) legally required by Treasury Regulation § 1.482-1(g) and (b) understated as a matter of economic analysis. Specifically, the Protest should:

(1) Establish the legal framework by citing Treas. Reg. § 1.482-1(g)(1) and (g)(2), demonstrating that correlative allocations are mandatory and that multiple § 482 adjustments must be reconciled to produce an aggregate allocation consistent with the arm's-length standard;

(2) Demonstrate the economic mechanism of overlap by walking through the interaction between the CSA adjustment and the royalty adjustment, as described in Section IV.A above, showing that both adjustments draw from the same pool of PBI income;

(3) Highlight the internal inconsistency in the IRS's positions: if the IRS's royalty adjustment is correct (i.e., the arm's-length royalty rate is 11.0%), then PBI's residual profitability is lower, which should reduce PBI's RAB share and thus its cost-sharing percentage under the CSA—partially or fully offsetting the proposed increase to that percentage. Conversely, if the IRS's CSA adjustment is correct (i.e., PBI's cost-sharing percentage should be higher, reflecting greater anticipated benefits), then PBI must be more profitable than the IRS's royalty adjustment assumes. The two positions are in tension, and the correlative offset is the mechanism for resolving that tension;

(4) Present the Whitmore Valuation Group's sensitivity analysis demonstrating that a properly computed correlative offset would reduce the net proposed adjustment by significantly more than $42.65 million, with quantified alternative offset scenarios; and

(5) Argue that the net proposed adjustment of $380.40 million exceeds the arm's-length result and should be reduced by the additional correlative offset amount identified by Whitmore, yielding a lower net adjustment.

The correlative adjustment argument should be presented as an independent ground for reducing the proposed adjustment, separate from PPC's substantive defenses on the royalty rate and CSA cost-sharing methodologies. This approach ensures that even if Appeals does not fully accept PPC's substantive positions (e.g., that the arm's-length royalty rate is 4.5% rather than 11.0%), PPC can still obtain a meaningful reduction based on the inadequacy of the correlative offset.

B. Presentation to Appeals Officer Castañeda

The correlative adjustment argument is well-suited for presentation at IRS Appeals, where the case has been assigned to Appeals Officer Noreen Castañeda. The Appeals conference is scheduled for February 28, 2024, at the IRS Appeals Office in Manhattan. The argument should be presented as follows:

(1) Frame the issue as one of internal consistency, not just taxpayer advocacy. The correlative offset is not a concession PPC is seeking; it is a correction required by the IRS's own regulations. The examination team has already recognized this by allowing the $42.65 million offset. PPC is merely arguing that the examination team did not go far enough.

(2) Demonstrate that even on the IRS's own assumptions, the net proposed adjustment overstates PPC's arm's-length income. By taking the IRS's proposed 11.0% royalty rate as a given and showing its feedback effect on the RAB calculation, PPC can demonstrate that the IRS's own positions imply a larger correlative offset—without PPC needing to concede that the 11.0% royalty rate is correct.

(3) Emphasize the hazards of litigation. If the case proceeds to the Tax Court, the IRS will face the challenge of defending two internally inconsistent positions. A Tax Court judge would likely recognize the tension between the CSA adjustment (positing a more profitable PBI) and the royalty adjustment (positing a less profitable PBI), and could reduce the aggregate adjustment accordingly. This litigation risk strengthens PPC's settlement position.

This argument is an independent ground for reducing the proposed adjustment, separate from PPC's substantive defenses on the royalty rate (CUT analysis with 14 comparables, interquartile range of 3.1% to 6.8%, median of 4.4%) and the CSA cost-sharing ratios. Presenting multiple independent grounds for reduction maximizes PPC's leverage at Appeals and increases the probability of a favorable settlement.

C. Settlement Implications

The corre

CALDERWOOD & HARKNESS LLP PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
This memorandum is protected by the attorney-client privilege and constitutes attorney work product prepared in anticipation of litigation. It is not to be disclosed to any person or entity outside the attorney-client relationship without the prior written authorization of Calderwood & Harkness LLP.
MEMORANDUM
TO: Leonard Cross, Responsible Partner Garrett Simmons, Lead Associate
FROM: Leila Nazari, Working Associate
DATE: October 25, 2023
RE: Availability and Mechanics of Correlative Adjustments Under Treas. Reg. § 1.482-1(g) — Penterra Pharmaceuticals Corp. IRS Examination Defense
Matter No.: 1018-00009
Client: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
Tax Years Under Examination: 2017, 2018, 2019, 2020
IRS Examination: LB&I-NE-TP-2022-00641
Right-click to update Table of Contents
I. Executive Summary
This memorandum analyzes the availability and mechanics of correlative adjustments under Treasury Regulation § 1.482-1(g) to prevent the double-counting of income arising from the Internal Revenue Service's concurrent proposed adjustments to (1) Penterra Pharmaceuticals Corp.'s ("PPC") cost-sharing arrangement ("CSA") with Penterra Biopharma International DAC ("PBI"), an Irish Designated Activity Company, and (2) the legacy intellectual property royalty rate between PPC and PBI. Both sets of adjustments operate on the same controlled group and, in significant measure, on the same underlying pool of PBI income. Unless properly reconciled through correlative allocations, the aggregate effect of both adjustments overstates PPC's arm's-length income and results in a net § 482 allocation that exceeds what the statute authorizes.
On October 12, 2023, the IRS issued a Notice of Proposed Adjustment ("NOPA") proposing total adjustments of $380.40 million across Tax Years 2017 through 2020. The NOPA comprises two principal components: (a) $235.01 million in CSA cost-sharing adjustments, reflecting the IRS's position that PBI's cost-sharing percentages should have been 8 to 12 percentage points higher than those reflected on PPC's returns; and (b) $188.04 million in royalty rate adjustments, reflecting the IRS's position that the legacy IP royalty rate should have been 11.0% of net sales rather than the 4.5% rate applied by the parties. To its credit, the examination team recognized a portion of the overlap and allowed a correlative offset of $42.65 million to avoid double-counting between the two adjustments, yielding the net proposed adjustment of $380.40 million.
This memorandum reaches three principal conclusions:
First, the $42.65 million correlative offset recognized by the examination team is both legally required and factually well-grounded. Treasury Regulation § 1.482-1(g)(1) mandates correlative allocations whenever the IRS makes a § 482 adjustment affecting a controlled group, and § 1.482-1(g)(2) further requires that the combined effect of multiple simultaneous adjustments be reconciled to produce an aggregate allocation consistent with the arm's-length standard—not more. The offset reflects the examination team's acknowledgment that a portion of the income captured by the royalty rate adjustment was already implicitly captured by the CSA cost-sharing adjustment.
Second, PPC has strong arguments that the $42.65 million offset understates the true economic overlap between the two adjustments. If the IRS's proposed 11.0% royalty rate is taken as correct, PBI's residual profits from legacy product lines would be significantly lower, which should proportionally reduce PBI's share of reasonably anticipated benefits ("RAB") and thus its required cost-sharing percentage under the CSA. The resulting feedback effect would reduce the CSA adjustment by more than the $42.65 million the examination team recognized. Preliminary sensitivity analyses performed by Dr. Helena Vasquez and Dr. Rohan Chakrabarti at Whitmore Valuation Group LLC suggest that a properly computed correlative offset could be materially larger—potentially in the range of $65 million to $90 million depending on the assumptions employed.
Third, the internal inconsistency inherent in the IRS's dual-adjustment position represents a significant hazard-of-litigation factor for IRS Appeals and, if necessary, for litigation in the United States Tax Court. The IRS cannot simultaneously maintain that PBI's cost-sharing ratio should be substantially higher (reflecting greater anticipated benefits) and that PBI's legacy IP royalty should be substantially higher (reducing PBI's residual profitability and, by extension, its anticipated benefits) without confronting the tension between these positions. This inconsistency should be featured prominently in PPC's Formal Protest, the filing deadline for which is December 22, 2023.
The correlative adjustment argument is independent of, and additive to, PPC's substantive defenses on the merits of the royalty rate (supported by a comparable uncontrolled transaction analysis identifying 14 comparables with an interquartile range of 3.1% to 6.8% and a median of 4.4%) and the CSA cost-sharing methodologies. Incorporation of this argument into the Formal Protest, presentation at IRS Appeals, and use in settlement negotiations are addressed in Section VII below.
II. Factual Background
A. PPC's Intercompany IP Structure
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA, with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company whose therapeutic focus areas include oncology, immunology, and rare-disease therapeutics. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC serves as the U.S. parent of a global group of affiliated entities and is the original developer and owner of the group's pharmaceutical intellectual property portfolio.
Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized under the laws of Ireland, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI functions as the group's intellectual property holding company and principal for commercial operations outside the Americas. PBI is tax resident in Ireland and subject to Irish corporation tax on its worldwide income. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. By the end of 2020, PBI employed approximately 185 individuals in Ireland, including commercial, medical affairs, regulatory, and administrative personnel engaged in the management and exploitation of the licensed IP portfolio.
PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is treated as a disregarded entity for U.S. federal income tax purposes under Treasury Regulation § 301.7701-3 and the entity classification election filed by PPC. PHL is, in turn, 100% owned by PPC. As a consequence of PHL's disregarded status, PBI's activities are attributed directly to PPC for purposes of the U.S. international tax provisions, including Subpart F, GILTI, and BEAT, subject to the check-the-box election treating PBI itself as a separate corporation for U.S. tax purposes.
Additionally, Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates as a contract manufacturer under a cost-plus transfer pricing arrangement with PBI, receiving cost plus a markup of 8% for manufacturing services performed on behalf of PBI. PMI employed approximately 620 individuals during the tax years under examination. PMI's activities include active pharmaceutical ingredient synthesis, formulation, fill-finish, and quality control testing for products destined for non-Americas markets.
The intercompany IP structure at issue in this examination involves two principal categories of intercompany transactions between PPC and PBI: (1) the cost-sharing arrangement governing jointly developed IP, and (2) the legacy IP royalty arrangement governing pre-existing compounds. These are described in Sections II.B and II.C below.
B. The Cost-Sharing Arrangement
Effective July 1, 2012, PPC and PBI entered into a Qualified Cost Sharing Arrangement (the "CSA") governed by Treasury Regulation § 1.482-7. Under the CSA, PBI acquired the rights to develop and exploit PPC's pharmaceutical intellectual property outside the Americas (defined as the United States, Canada, Mexico, Central America, South America, and the Caribbean) in exchange for two categories of consideration:
First, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC at the inception of the CSA. The PCT payment compensated PPC for making available to the CSA the existing platform of pharmaceutical IP—including patents, trade secrets, clinical data, regulatory filings, and know-how—that PPC had developed prior to the CSA's effective date and that would serve as the foundation for future joint development activities. The PCT payment was determined using a discounted cash flow methodology, as required under Treasury Regulation § 1.482-7(g).
Second, PBI has made, and continues to make, ongoing cost-sharing payments to PPC. These payments represent PBI's share of the intangible development costs ("Coss") incurred by PPC in conducting research and development activities that benefit both parties to the CSA. PBI's share is determined annually based on its reasonably anticipated benefits ("RAB") from the CSA, expressed as a percentage of total RAB. The RAB methodology employed by PPC and PBI uses projected sales-based profit metrics, consistent with the regulatory framework under § 1.482-7(e)(2)(ii).
PBI's cost-sharing percentages for the tax years under examination, and the corresponding dollar amounts, were as follows:
The upward trend in PBI's cost-sharing percentages over the 2017–2020 period reflects PBI's growing share of anticipated benefits as several CSA-covered compounds received regulatory approvals and achieved commercial launch in non-Americas markets. The RAB projections underlying these percentages were updated annually by PPC's transfer pricing team in consultation with independent economists, and the methodology and results were documented in PPC's contemporaneous transfer pricing documentation for each tax year.
C. The Legacy IP Royalty Arrangement
Separate and apart from the CSA, PBI holds a license from PPC to exploit certain legacy pharmaceutical compounds in the non-Americas territory. These legacy compounds—principally those with patent filings and initial clinical development predating the July 1, 2012 effective date of the CSA—were carved out of the CSA and instead made available to PBI under a standalone intercompany licensing agreement. Under this license, PBI pays PPC a royalty of 4.5% of net sales generated by the legacy compounds in the non-Americas territory.
The 4.5% royalty rate was established by PPC at the time of the initial licensing arrangement based on a comparable uncontrolled transaction ("CUT") analysis identifying arm's-length royalty rates for licenses of pharmaceutical compounds at a comparable stage of development and with comparable risk profiles. PPC's contemporaneous transfer pricing documentation describes the CUT analysis and its conclusions in detail.
The legacy compound non-Americas net sales and corresponding royalties for the tax years under examination were as follows:
The declining trajectory of legacy compound net sales reflects the natural lifecycle of these products as they faced generic competition, patent expiration, and declining market share in various non-Americas jurisdictions. This decline is relevant to the IRS's royalty rate adjustment and to the correlative offset calculation, as discussed below.
D. The IRS's Proposed Adjustments (NOPA, October 12, 2023)
On October 12, 2023, the IRS examination team issued a Notice of Proposed Adjustment encompassing two categories of § 482 adjustments for Tax Years 2017 through 2020, together with a partial correlative offset and a proposed penalty. Each component is described below.
1. CSA Cost-Sharing Adjustments ($235.01 Million Total)
The IRS proposed increasing PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points per year, on the basis that PPC's RAB methodology underestimated PBI's share of anticipated benefits from the jointly developed IP. The IRS's proposed adjustments are as follows:
The IRS's position rests primarily on two contentions: (a) that PPC's RAB projections underestimated the growth potential of the non-Americas markets for CSA-covered compounds, and (b) that PPC failed to adequately account for the value of pre-existing intangibles (beyond the PCT payment) that continued to benefit PBI's commercial operations.
2. Royalty Rate Adjustments ($188.04 Million Total)
Separately, the IRS proposed increasing the legacy IP royalty rate from 4.5% of net sales to 11.0% of net sales, contending that PPC's CUT analysis was deficient and that the arm's-length royalty rate for the licensed legacy compounds should be materially higher. The year-by-year adjustments are as follows:
The IRS's royalty rate adjustment is based on the examination team's application of a CUT analysis using comparables that PPC contends are materially dissimilar (as discussed in separate memoranda addressing the substantive royalty rate defense).
3. Correlative Offset Allowed by Examination ($42.65 Million)
Recognizing the potential for double-counting, the examination team allowed a correlative offset of $42.65 million as a reduction to the combined proposed adjustment. This offset was computed by the IRS's economist, Dr. Alan Washburne, and reviewed by IRS Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi. Revenue Agent Patricia Dunleavy and Supervisory Revenue Agent Gerald Meskill approved the inclusion of the offset in the final NOPA.
4. Net Proposed Adjustment
The net proposed adjustment is calculated as follows:
5. Proposed Penalty
The NOPA proposes a penalty under IRC § 6662(e) for substantial valuation misstatement. The penalty is calculated at 20% of the underpayment attributable to the net § 482 allocation:
$380.40 million × 21% (corporate tax rate) × 20% (penalty rate) ≈ $15.98 million
The penalty calculation applies the 21% corporate rate for TY 2018–2020; for TY 2017, a blended rate reflecting the pre-TCJA 35% rate for the portion of the year before December 22, 2017, and the post-TCJA 21% rate thereafter would be technically applicable, though the NOPA appears to have used 21% across all years as a simplification.
E. The Overlap / Double-Counting Problem
The central issue addressed in this memorandum is the economic and legal overlap between the CSA cost-sharing adjustment and the royalty rate adjustment, which creates a double-counting problem that the correlative offset is intended to address.
The CSA cost-sharing ratio is driven by RAB projections, which measure each party's anticipated benefits from the jointly developed IP. The RAB calculation is forward-looking and depends on assumptions about the future profitability of each participant's exploitation of the CSA-covered intangibles. Critically, while the CSA and legacy royalty arrangements are nominally separate transactions, they operate on the same entity—PBI—and PBI's overall financial profile, including its profitability from all sources, can influence the economic analysis underlying the RAB determination.
When the IRS simultaneously (a) increases the cost-sharing ratio (thereby allocating more R&D costs to PBI and reducing PBI's net income from CSA-covered activities) and (b) increases the royalty rate on legacy IP (thereby allocating more royalty income to PPC and further reducing PBI's net income from legacy product lines), both adjustments seek to increase PPC's U.S.-source income from the same overall intercompany relationship with PBI. To the extent both adjustments capture overlapping portions of PBI's income—that is, the higher royalty reduces PBI's residual profit, which in turn would already be reflected in a properly adjusted RAB calculation—a correlative offset is necessary to prevent overstatement of PPC's allocable income.
More specifically, the mechanism of overlap operates as follows: If PBI is required to pay a higher royalty rate (11.0% rather than 4.5%) on legacy compound net sales, PBI's aggregate profitability declines. Under the RAB methodology, PBI's anticipated benefits from the CSA are measured, in part, by reference to PBI's projected income. A lower overall profitability for PBI would translate into a lower RAB share for PBI, which would in turn reduce PBI's required cost-sharing percentage. The IRS's proposed CSA adjustment, however, increases PBI's cost-sharing percentage without fully accounting for the profit-reducing effect of the simultaneously proposed royalty rate increase. The result is an aggregate adjustment that attributes more income to PPC than would be the case if both adjustments were computed on a consistent basis.
The $42.65 million offset represents the examination team's partial recognition of this problem. As discussed in Section IV below, PPC has grounds to argue that the offset is insufficient and that a properly computed correlative adjustment would be materially larger.
III. Legal Framework: Treas. Reg. § 1.482-1(g) — Correlative Allocations
A. Statutory Authority — IRC § 482
Internal Revenue Code § 482 provides the Secretary of the Treasury with broad authority to reallocate income, deductions, credits, and allowances among commonly controlled entities in order to prevent the evasion of taxes or to clearly reflect the income of such entities. The statute reads, in relevant part:
"In any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, the Secretary may distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses, if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses."
The implementing regulations under § 482 establish the arm's-length standard as the governing principle for evaluating controlled transactions. Treasury Regulation § 1.482-1(b)(1) provides that a controlled transaction meets the arm's-length standard if the results of the transaction are consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. This standard is the touchstone against which all § 482 adjustments must be measured. An adjustment that exceeds the arm's-length amount is as impermissible as one that falls short of it; the statute authorizes allocation of the arm's-length amount, and no more.
The best method rule, set forth in Treasury Regulation § 1.482-1(c), requires the selection of the pricing method that provides the most reliable measure of an arm's-length result under the facts and circumstances of each case. The best method rule is relevant here because the IRS's simultaneous application of separate methods to the CSA and royalty transactions must yield results that are collectively consistent with arm's-length outcomes when viewed in the aggregate.
B. Treas. Reg. § 1.482-1(g)(1) — In General
Treasury Regulation § 1.482-1(g)(1) establishes the fundamental principle of correlative allocations. The regulation provides:
"When the district director makes an allocation under section 482, appropriate correlative allocations will be made with respect to any other member of the group affected by the allocation."
The purpose of the correlative allocation requirement is straightforward: a § 482 allocation that increases the income of one member of a controlled group necessarily implies a corresponding decrease in the income of another member of the group. The correlative allocation ensures that the total income of the controlled group is neither overstated nor understated—i.e., that the § 482 reallocation is a zero-sum exercise within the group. Without a correlative adjustment, an upward allocation to one entity would increase the aggregate income of the group beyond the arm's-length amount, resulting in double taxation of a portion of the group's income.
The correlative allocation is made automatically as a matter of law. It is not discretionary. The regulation uses the mandatory term "will be made," not "may be made." The IRS is obligated to make appropriate correlative allocations whenever it exercises its authority under § 482, and the taxpayer is entitled to the benefit of such allocations. This principle has been consistently upheld in the case law and is foundational to the administration of the transfer pricing rules.
C. Treas. Reg. § 1.482-1(g)(2) — Correlative Allocations Where More Than One Adjustment
When the IRS makes multiple § 482 allocations affecting the same controlled group—as it has done here, with the CSA adjustment and the royalty adjustment both affecting PPC and PBI—Treasury Regulation § 1.482-1(g)(2) requires that the combined effect of all allocations be consistent with the arm's-length standard. This provision operates as a check on the IRS's authority: the IRS may not make separate adjustments that, taken individually, might each be defensible, but that in the aggregate exceed the arm's-length result for the controlled group.
The regulation reflects a recognition that controlled transactions do not exist in isolation. When two intercompany transactions involve the same parties and draw upon the same pool of the foreign affiliate's income, adjustments to those transactions can interact in ways that produce overlapping income inclusions. The correlative allocation mechanism under § 1.482-1(g)(2) requires that these interactions be identified and reconciled so that the aggregate income allocated to the U.S. taxpayer equals the arm's-length amount—not a higher amount that results from treating each transaction as if it existed independently.
This requirement implicates the broader debate between the "aggregate" and "transactional" approaches to § 482 adjustments. Under a purely transactional approach, each controlled transaction is analyzed separately, and the arm's-length price for each transaction is determined independently. Under an aggregate approach, the combined effect of all controlled transactions between the parties is evaluated to determine whether the overall results are consistent with arm's-length outcomes. The regulations generally adopt a transactional approach, see Treas. Reg. § 1.482-1(d)(3)(ii), but the correlative allocation provisions of § 1.482-1(g) serve as a critical safety valve, ensuring that the transactional approach does not produce aggregate results that exceed the arm's-length standard. Where two transactional adjustments interact to produce overlapping income inclusions, the regulations mandate a correlative reconciliation.
D. Treas. Reg. § 1.482-1(g)(3) — Procedures for Correlative Allocations
Treasury Regulation § 1.482-1(g)(3) sets forth the procedures by which the affected member of the controlled group (here, PBI) obtains the benefit of a correlative downward adjustment when the other member's income (here, PPC's income) is adjusted upward. The regulation provides that the correlative allocation is reflected on the return of the affected member for the taxable year to which the § 482 allocation relates.
In PPC's case, the procedural posture is somewhat simplified by the corporate ownership structure. PBI is owned by PHL, which is treated as a disregarded entity for U.S. federal tax purposes. PHL is, in turn, owned directly by PPC. As a result, the correlative allocation effectively operates on a consolidated or aggregated basis on PPC's U.S. return in terms of computing the net § 482 adjustment. The upward adjustment to PPC's income (reflecting higher cost-sharing payments from PBI and higher royalty income from PBI) and the correlative downward adjustment to PBI's income (reflecting PBI's lower residual profits) are both accounted for within the same U.S. tax return framework, given PBI's status as a controlled foreign corporation ("CFC") whose income flows through to PPC under the Subpart F and GILTI regimes.
It is important, however, to distinguish between two different concepts that the term "correlative allocation" can describe. The first is the mechanical correlative allocation required by § 1.482-1(g)(1)—the reduction of PBI's income to mirror PPC's increase. The second is the practical need to avoid double-counting when two adjustments apply to the same income stream. The $42.65 million offset at issue in this memorandum is an example of the latter: it is not merely a mirror-image reduction of PBI's income, but rather a reconciliation of two separate adjustments that, absent the offset, would collectively attribute more income to PPC than the arm's-length standard permits. Both concepts are grounded in the same regulatory authority—§ 1.482-1(g)—but they operate at different levels of the analysis.
E. Treas. Reg. § 1.482-1(g)(4) — Conforming Adjustments to Other Tax Items
Treasury Regulation § 1.482-1(g)(4) requires that when a § 482 allocation is made, conforming adjustments must be made to all affected tax items. The regulation recognizes that a § 482 allocation does not exist in a vacuum; it has ripple effects throughout the tax system that must be accounted for to produce a coherent result.
Specifically, the conforming adjustments may include, but are not limited to:
(a) Adjustments to withholding tax liability on royalty payments, dividends, or other intercompany payments that are increased or decreased as a result of the § 482 allocation;
(b) Adjustments to foreign tax credit computations under IRC §§ 901–909, reflecting changes in the sourcing and categorization of income;
(c) Adjustments to the earnings and profits of the affected CFC(s), under IRC § 312 and related provisions;
(d) Adjustments to Subpart F income inclusions, to the extent the § 482 allocation alters the character or amount of the CFC's income that is subject to current inclusion under IRC §§ 951–964;
(e) Adjustments to tested income for purposes of the Global Intangible Low-Taxed Income ("GILTI") inclusion under IRC § 951A, applicable for TY 2018–2020; and
(f) Adjustments to the base erosion and anti-abuse tax ("BEAT") calculation under IRC § 59A, to the extent the § 482 allocation affects the amount of base erosion payments.
Each of these conforming adjustments is relevant to PPC's examination. The GILTI and BEAT implications of the proposed adjustments are discussed in Section VI.B below, and a full quantitative analysis of these interactions is being prepared in a separate memorandum. The earnings and profits and Subpart F implications are discussed in Section VI.D.
IV. Application to PPC's Examination: The $42.65 Million Correlative Offset
A. Nature of the Overlap Between CSA and Royalty Adjustments
The CSA adjustment and the royalty adjustment proposed in the NOPA create overlapping income allocations to PPC through the following mechanism:
CSA Adjustment — Reducing PBI's Post-CSA Residual Profit. The CSA adjustment increases PBI's required cost-sharing payment to PPC. By raising PBI's cost-sharing percentage (from 38.2%–42.7% to 48.2%–53.7%), the IRS requires PBI to bear a larger share of the total R&D costs. The additional cost-sharing payments flow from PBI to PPC, reducing PBI's post-CSA residual profit from the exploitation of CSA-covered IP and correspondingly increasing PPC's income. Over the four-year period, this component allocates an additional $235.01 million of income to PPC.
Royalty Adjustment — Further Reducing PBI's Profit. The royalty adjustment increases PBI's royalty payment to PPC on legacy IP from 4.5% to 11.0% of net sales. The additional royalty payments flow from PBI to PPC, reducing PBI's profit from the legacy product lines and correspondingly increasing PPC's royalty income. Over the four-year period, this component allocates an additional $188.04 million of income to PPC.
The Interaction. Both adjustments operate on PBI's income. The CSA adjustment draws from PBI's income attributable to CSA-covered IP, and the royalty adjustment draws from PBI's income attributable to legacy IP. At first blush, these might appear to be independent adjustments affecting different income streams. However, they interact through the RAB calculation that determines PBI's cost-sharing percentage under the CSA.
The RAB calculation is a forward-looking assessment of each participant's anticipated benefits from the CSA. PBI's anticipated benefits are a function of its projected profitability from the exploitation of CSA-covered IP in the non-Americas territory. While the RAB calculation is, in principle, limited to benefits attributable to the CSA-covered IP (rather than the legacy IP), the two income streams are not entirely independent. PBI's overall financial profile—including its profitability from legacy products—affects its capacity to invest in commercialization, its market presence, and its infrastructure, all of which bear on the anticipated benefits it will derive from CSA-covered products.
More importantly, the IRS's own methodology for computing the RAB shares implicitly incorporates assumptions about PBI's overall profitability. To the extent the IRS's proposed 11.0% royalty rate would, if applied, reduce PBI's aggregate income, that reduced income should, in a consistent analysis, feed back into the RAB calculation and lower PBI's share of anticipated benefits. In other words, a PBI that is paying 11.0% royalties on legacy compounds (instead of 4.5%) is a less profitable PBI, and a less profitable PBI would be expected to derive lower anticipated benefits from the CSA—which should translate into a lower, not higher, cost-sharing percentage.
The $42.65 million offset reflects the examination team's recognition that a portion of the income captured by the royalty rate adjustment was already implicitly captured by the CSA cost-sharing adjustment. Without the offset, the aggregate adjustment of $423.05 million ($235.01M + $188.04M) would attribute more income to PPC than the arm's-length result permits. The offset brings the net adjustment to $380.40 million, but as discussed in Section IV.C, PPC has grounds to argue that even this reduced amount overstates PPC's arm's-length income.
B. Calculation Mechanics of the $42.65 Million Offset
The correlative offset of $42.65 million was computed by the IRS's economist, Dr. Alan Washburne, as part of the NOPA calculations. Based on the NOPA and supporting workpapers provided by the examination team, the offset was derived as follows:
The offset addresses the extent to which higher royalty payments from PBI to PPC (reflecting the proposed 11.0% royalty rate) would, if properly reflected in the RAB calculation, reduce PBI's cost-sharing percentage—partially offsetting the proposed increase to that percentage. The offset is, in essence, a "feedback" adjustment: it reduces the CSA adjustment to account for the profit-reducing effect of the royalty adjustment on PBI's anticipated benefits.
The year-by-year allocation of the $42.65 million offset, based on the relative magnitude of the overlapping adjustments in each year, is as follows:
Several observations merit note regarding these calculations:
First, the offset is proportionally larger in earlier years (2017 and 2018), when the legacy compound net sales were higher and the royalty adjustment had a greater absolute impact on PBI's profitability. This is consistent with the economic logic underlying the offset: a larger royalty adjustment has a greater feedback effect on PBI's anticipated benefits and thus a greater impact on the RAB calculation.
Second, the examination team's workpapers indicate that the offset was computed using a partial-equilibrium approach—i.e., the feedback effect of the royalty adjustment on the RAB calculation was estimated at a single iteration rather than solved to convergence. This methodological choice may understate the true offset, as a fully iterated computation would capture second-order effects (e.g., the reduced cost-sharing percentage would itself affect PBI's profitability, which would further affect the RAB calculation).
Third, the offset was reviewed and approved by IRS Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi, and was included in the NOPA as signed by Revenue Agent Patricia Dunleavy and approved by Supervisory Revenue Agent Gerald Meskill. The fact that the IRS has already conceded the need for a correlative offset—and has quantified it at $42.65 million—is significant for PPC's position. It establishes a floor: the IRS cannot credibly argue at Appeals or in litigation that no offset is required, having already allowed one in the NOPA. The only question is whether the offset should be larger.
C. Argument That the $42.65 Million Offset Is Insufficient
PPC's position, to be developed in the Formal Protest and presented at Appeals, should argue that the $42.65 million correlative offset understates the true economic overlap between the CSA and royalty adjustments. The argument has several components:
1. The RAB Feedback Effect Is Understated. If the IRS's proposed 11.0% royalty rate is taken as correct, PBI's residual profits from legacy product lines would be significantly lower than those reflected in PPC's reported positions. The incremental royalty payments of $188.04 million over four years represent a substantial reduction in PBI's aggregate profitability. Under the RAB methodology, PBI's anticipated benefits from the CSA are a function of its projected income. A PBI that is paying $188 million more in royalties over the period is, by definition, a less profitable entity with lower anticipated benefits from the CSA. This should proportionally reduce PBI's RAB share and thus its required cost-sharing percentage—potentially by more than the 8 to 12 percentage point increase the IRS proposes.
To illustrate: if PBI's RAB share were recalculated using the IRS's proposed 11.0% royalty rate as an input (rather than the 4.5% rate reflected in PPC's returns), the resulting cost-sharing ratios for PBI would be lower than those proposed by the IRS. The magnitude of the reduction depends on the specific RAB model and assumptions employed, but preliminary modeling by Whitmore Valuation Group suggests that the cost-sharing percentages, after accounting for the royalty adjustment, would be approximately 2 to 5 percentage points lower than the IRS's proposed percentages—implying a correlative offset significantly larger than $42.65 million.
2. Sensitivity Analysis. Dr. Helena Vasquez and Dr. Rohan Chakrabarti at Whitmore Valuation Group LLC (200 Ashbury Asset Advisors, Suite 700, Boston, MA 02109) have modeled alternative offset scenarios under the Kovel arrangement (letter reference 1018-00009-KV, executed June 20, 2022) pursuant to which Whitmore performs its analysis under the protection of attorney-client privilege. Whitmore's blended billing rate is $650 per hour. Their preliminary findings indicate:
(a) If PBI's RAB is recalculated using the 11.0% royalty rate and a fully iterated convergence methodology, the correlative offset would be approximately $78.3 million — nearly double the $42.65 million allowed by the examination team.
(b) If additional feedback effects are considered (including the impact of reduced PBI profitability on PBI's market development capacity and projected sales growth), the offset could reach approximately $91.6 million.
(c) Under a conservative midpoint estimate, the correlative offset should be no less than $65 million, representing a $22.35 million increase over the examination team's figure.
3. Internal Inconsistency as a Hazard-of-Litigation Factor. The internal inconsistency in the IRS's position is a significant vulnerability. The IRS cannot simultaneously maintain that PBI's cost-sharing ratio should be substantially higher (reflecting greater anticipated benefits from the CSA) and that PBI's legacy IP royalty should be substantially higher (reducing PBI's residual profitability and, by extension, its capacity to generate anticipated benefits from any source). These two positions are in tension: one posits a more profitable PBI (higher RAB share), while the other posits a less profitable PBI (higher royalty payments). At Appeals, this inconsistency can be highlighted as evidence that the IRS's aggregate proposed adjustment exceeds the arm's-length result, strengthening PPC's case for a larger correlative offset and a lower net adjustment.
4. Burden of Proof Considerations. Under IRC § 7491(a), the burden of proof on a factual issue shifts to the IRS in a Tax Court proceeding if the taxpayer has maintained adequate records and has cooperated with the IRS's reasonable requests for information. PPC has maintained contemporaneous transfer pricing documentation for each year and has cooperated fully with the examination. If the case proceeds to litigation, PPC can argue that the IRS bears the burden of proving that its $42.65 million offset is the correct amount, and that PPC's evidence (including the Whitmore sensitivity analysis) demonstrates that the correct amount is higher.
V. Case Law Supporting Correlative Adjustments
A. General Principles
The requirement of correlative adjustments in § 482 cases has been recognized and enforced by the Tax Court and the federal courts of appeals in a consistent line of precedent. The overarching principle is that IRC § 482 authorizes the IRS to allocate the arm's-length amount of income—and no more. An allocation that, in the aggregate, exceeds the arm's-length result for the controlled group violates the statute, regardless of whether the individual components of the allocation might be defensible in isolation.
This principle is a direct corollary of the arm's-length standard itself. Treasury Regulation § 1.482-1(b)(1) requires that controlled transactions produce results consistent with those that uncontrolled parties would achieve. If two uncontrolled parties entered into both a cost-sharing arrangement and a separate licensing agreement, the terms of each transaction would reflect the parties' overall economic relationship. An uncontrolled licensee paying a higher royalty rate would negotiate a lower cost-sharing percentage (or a lower PCT payment) to compensate, and vice versa. The correlative adjustment ensures that the IRS's allocations replicate this market dynamic rather than ignoring it.
The courts have also recognized that § 482 is a tool for "clearly reflecting income"—not for maximizing the U.S. fisc's revenue. The Supreme Court in Commissioner v. First Security Bank of Utah, N.A., 405 U.S. 394 (1972), emphasized that § 482 is to be applied in a manner that produces a fair reflection of income, not a punitive one. The corollary is that the IRS may not use § 482 to "whipsaw" a taxpayer by making inconsistent adjustments that collectively exceed the arm's-length result. See also Crowne Albany Industries v. Commissioner, 856 F.2d 855 (7th Cir. 1988) (discussing the purpose and limits of § 482 adjustments).
B. Relevant Precedent
Several lines of precedent are relevant to PPC's correlative adjustment argument:
1. Multiple Intercompany Transactions and the Anti-Whipsaw Principle. Courts have recognized that when the IRS makes adjustments to multiple intercompany transactions between the same controlled parties, the adjustments must be internally consistent. The IRS may not, for example, increase the price of one intercompany transaction on the ground that the U.S. entity's contribution of value was higher, while simultaneously increasing the price of a different intercompany transaction on the ground that the U.S. entity's contribution of value to the same overall relationship was also higher, if the two adjustments together attribute more value to the U.S. entity than the entity actually contributed.
In Bausch & Lomb, Inc. v. Commissioner, 92 T.C. 525 (1989), aff'd, 933 F.2d 1084 (2d Cir. 1991), the Tax Court examined the IRS's authority to make § 482 adjustments and recognized that the arm's-length standard imposes a ceiling on the aggregate adjustment. While the specific facts of Bausch & Lomb involved a different configuration of intercompany transactions, the principle is directly applicable: the IRS's authority under § 482 is bounded by the arm's-length result, and correlative adjustments are the mechanism by which that boundary is enforced when multiple adjustments are made.
2. CSA-Specific Precedent. The interaction between CSA adjustments and other § 482 adjustments has been considered in the modern cost-sharing litigation. In Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), remanded to T.C., T.C. Memo. 2022-84, the Eighth Circuit addressed the IRS's proposed § 482 adjustments to intercompany royalty and other transfer pricing arrangements involving Harborview Corporation's Puerto Rico operations. While the Harborview Corporation case primarily concerned the appropriate method for valuing intercompany IP transfers (and the Tax Court on remand applied a modified CUT analysis), the case is instructive for PPC's purposes because it illustrates the principle that the IRS's proposed adjustments must be internally consistent and that the Tax Court has authority to determine the correct arm's-length result even if it differs from both the taxpayer's and the IRS's positions.
In Altera Corp. v. Commissioner, 145 T.C. 91 (2015), rev'd, 941 F.3d 1200 (9th Cir. 2019), cert. denied, 141 S. Ct. 131 (2020), the Ninth Circuit addressed the validity of Treasury Regulation § 1.482-7(d)(2) (the stock-based compensation cost-sharing regulation) and its consistency with the arm's-length standard. Although Altera does not directly address correlative adjustments, the decision's emphasis on the arm's-length standard as the governing constraint on § 482 regulations supports PPC's argument that the aggregate effect of the IRS's adjustments must conform to the arm's-length standard—and that a correlative offset is the mechanism for achieving that conformity.
3. Consistency Requirement and the IRS's Obligation to Reconcile. The Tax Court has consistently held that the IRS bears the burden of demonstrating that its proposed § 482 adjustments clearly reflect income. See, e.g., Sundstrand Corp. v. Commissioner, 96 T.C. 226, 353 (1991) (holding that the IRS's determinations under § 482 are entitled to a presumption of correctness, but that the taxpayer may rebut this presumption by showing that the adjustments do not clearly reflect income). When the taxpayer demonstrates that two simultaneous adjustments produce overlapping income inclusions, the IRS's presumption of correctness as to the aggregate adjustment is weakened, and the IRS must justify the combined amount.
4. OECD Transfer Pricing Guidelines as Persuasive Authority. The OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017, as updated in 2022) serve as persuasive (though not binding) authority in U.S. transfer pricing cases. The Guidelines support the principle that correlative adjustments are necessary to avoid double taxation when multiple transfer pricing adjustments are made to transactions between the same controlled parties.
Chapter I of the Guidelines (Arm's Length Principle) emphasizes at Paragraph 1.6 that the arm's-length principle should be applied consistently across all controlled transactions, and that adjustments to one transaction may need to be reconciled with adjustments to other transactions involving the same parties. Chapter VIII (Cost Contribution Arrangements) addresses the interaction between cost-sharing adjustments and other transfer pricing adjustments at Paragraphs 8.39–8.44, noting that adjustments to a CCA participant's cost-sharing percentage must be consistent with the overall allocation of income between the participants.
The 2022 revisions to the OECD Guidelines further reinforce the principle that correlative adjustments are necessary to prevent double taxation, particularly in the context of simultaneous adjustments by the same tax administration. While the OECD Guidelines' treatment of corresponding adjustments (Chapter IV) primarily addresses bilateral adjustments between two countries, the underlying principle—that adjustments should not result in an aggregate allocation exceeding the arm's-length amount—is equally applicable to multiple adjustments by a single tax authority affecting the same controlled group.
VI. Interaction with Other Provisions
A. IRC § 367(d) — Outbound IP Transfer
A separate memorandum analyzes the risk that the IRS may seek to recharacterize the CSA (or the PCT payment component thereof) as an outbound transfer of intangible property subject to IRC § 367(d). Under § 367(d), a U.S. person who transfers intangible property to a foreign corporation in a § 351 exchange or a § 361 reorganization is treated as having sold the property in exchange for annual payments contingent on the productivity, use, or disposition of the intangible—i.e., an imputed royalty stream.
If the IRS were to recharacterize the CSA as a § 367(d) outbound transfer, correlative adjustments would still be required under Treasury Regulation § 1.482-1(g) to avoid double-counting with any royalty adjustments. Specifically:
(a) The § 367(d) annual inclusion mechanism would require PPC to include in income an amount reflecting the arm's-length royalty for the transferred intangibles. This amount would need to be reconciled with the royalty income already being allocated to PPC under the legacy IP royalty adjustment. If both the § 367(d) inclusion and the royalty adjustment captured overlapping value attributable to the same intangible property, a correlative offset would be mandatory.
(b) Similarly, the § 367(d) inclusion would need to be reconciled with the CSA cost-sharing adjustment. To the extent the cost-sharing adjustment already captures a portion of the value that would otherwise be allocated through a § 367(d) inclusion, the two cannot both apply to their full amounts without exceeding the arm's-length result.
While the § 367(d) recharacterization risk is addressed in a separate memorandum, the correlative adjustment analysis set forth herein applies with equal force to any alternative characterization of the CSA that the IRS might advance.
B. GILTI (IRC § 951A) and BEAT (IRC § 59A) Implications
For Tax Years 2018 through 2020 (the post-Tax Cuts and Jobs Act period, during which the federal corporate tax rate is 21%), the correlative adjustment has significant implications for PPC's Global Intangible Low-Taxed Income ("GILTI") inclusion under IRC § 951A and its base erosion and anti-abuse tax ("BEAT") liability under IRC § 59A.
GILTI Implications. PBI is a controlled foreign corporation ("CFC") whose tested income is subject to the GILTI regime. The correlative adjustment affects PBI's tested income as follows: A larger correlative offset reduces PPC's § 482 adjustment (reducing PPC's directly allocated income) but correspondingly increases PBI's tested income (because PBI retains more of its profits). To the extent PBI's increased tested income flows through to PPC as a GILTI inclusion, the net effect of a larger correlative offset on PPC's total U.S. tax liability is partially offset by the increased GILTI inclusion.
However, the GILTI inclusion is not dollar-for-dollar: the GILTI regime provides for a 50% deduction under IRC § 250(a)(1)(B) (reducing the effective rate on GILTI income to approximately 10.5% before considering foreign tax credits), and PPC may be entitled to foreign tax credits under IRC § 960 for Irish taxes paid by PBI on the additional tested income. As a result, a dollar of income that shifts from direct § 482 adjustment (taxed at 21%) to GILTI inclusion (effectively taxed at approximately 10.5%, less foreign tax credits) produces a net tax saving to PPC. This asymmetry further supports PPC's argument for a larger correlative offset, as the net tax cost of the offset is lower than the IRS's calculation might suggest.
BEAT Implications. The royalty adjustment increases the amount of intercompany royalty payments from PBI to PPC. Under the BEAT regime, base erosion payments to foreign related parties are added back to the modified taxable income base for purposes of computing the BEAT liability. To the extent the royalty adjustment increases the characterization of amounts paid by PBI to PPC as "royalties" (an item that could, in certain analytical frameworks, be viewed as a base erosion payment from the reverse perspective), the interaction with the BEAT calculation must be carefully modeled. In PPC's case, because the royalty flows from the foreign entity (PBI) to the domestic parent (PPC), the BEAT implications primarily affect the computation of PPC's regular tax liability rather than creating a BEAT exposure per se. However, the conforming adjustment to PBI's earnings and profits may have indirect BEAT consequences that must be quantified.
These GILTI and BEAT interactions must be modeled quantitatively to determine the net effect on PPC's total U.S. tax liability. A detailed quantitative analysis is being prepared in a separate memorandum.
TY 2017 Considerations. Tax Year 2017 was subject to the pre-TCJA 35% corporate tax rate for the majority of the year (January 1 through December 21, 2017), with the post-TCJA 21% rate applying for the period from December 22 through December 31, 2017. The GILTI and BEAT provisions were not yet in effect for TY 2017, and accordingly, the correlative adjustment analysis for TY 2017 is simpler: the § 482 adjustment is taxed at the blended TY 2017 rate (approximately 34% for a calendar-year taxpayer) without the offsetting GILTI/BEAT considerations.
C. Competent Authority / Mutual Agreement Procedure
If the § 482 adjustments result in economic double taxation—that is, if the upward adjustment to PPC's U.S. income is not matched by a corresponding downward adjustment to PBI's Irish income—PPC may seek relief under the income tax treaty between the United States and Ireland (Convention between the Government of the United States of America and the Government of Ireland for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital Gains, signed November 28, 1997, as amended by the 1999 Protocol). Article 25 of the treaty provides for a mutual agreement procedure ("MAP") through which the competent authorities of the two countries may seek to resolve cases of taxation not in accordance with the treaty.
The correlative adjustment under Treasury Regulation § 1.482-1(g) is a domestic mechanism: it reconciles the U.S. tax treatment of the controlled transactions but does not, by itself, produce a corresponding adjustment on the Irish side. To the extent Ireland does not reduce PBI's Irish taxable income to reflect the U.S. § 482 adjustments, PPC faces the prospect of double taxation of the same income—once in the United States (through the § 482 adjustment) and once in Ireland (through PBI's Irish tax return, which continues to reflect the original intercompany pricing).
A competent authority request / MAP filing would require coordination between PPC's U.S. counsel and PBI's Irish tax advisors. PBI is advised on Irish tax matters by Thornbury & Keogh, led by Ciarán Thornbury, at 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland. Any MAP filing would need to be prepared in coordination with Thornbury & Keogh to ensure that the Irish competent authority is presented with a consistent factual and legal narrative.
The timing of a MAP filing depends on the resolution of the U.S. examination. Revenue Procedure 2015-40 provides the procedural framework for requesting competent authority assistance, including the requirement that a request generally be made within a specified period after the IRS proposes its adjustments. PPC should be mindful of this deadline and prepared to file a protective MAP request if the examination is not resolved at Appeals within a reasonable timeframe.
D. Earnings and Profits / Subpart F
A § 482 adjustment to PPC's income triggers conforming adjustments to PBI's earnings and profits under Treasury Regulation § 1.482-1(g)(4) and IRC § 312. Specifically:
(a) The upward adjustment to PPC's income (reflecting higher cost-sharing payments and higher royalties from PBI) results in a corresponding downward adjustment to PBI's current earnings and profits for the relevant tax years. This reduction in PBI's E&P may affect PBI's accumulated E&P balance, which in turn affects the characterization of any distributions from PBI (or deemed distributions, such as those arising under IRC § 956).
(b) To the extent PBI has Subpart F income under IRC § 952 (e.g., foreign base company sales income or foreign personal holding company income from royalty payments to PPC), the § 482 adjustment may alter the amount of Subpart F income includible in PPC's gross income. Specifically, if the royalty rate adjustment increases the amount of PBI's royalty payments to PPC, PBI's deductible expense increases, reducing PBI's net income and potentially reducing the amount of Subpart F income.
(c) The conforming adjustment to PBI's E&P also affects the computation of previously taxed earnings and profits ("PTEP") under IRC § 959, which in turn affects the treatment of future distributions from PBI to PHL (and, by extension, to PPC). An increase in the § 482 adjustment to PPC's income may generate additional PTEP that would shield future distributions from further taxation.
(d) Additionally, the withholding tax implications must be considered. Under Article 12 of the U.S.-Ireland income tax treaty, royalties paid by PBI (an Irish entity) to PPC (a U.S. entity) are generally exempt from Irish withholding tax, provided the beneficial owner is a resident of the other contracting state and holds a specified ownership interest. To the extent the § 482 adjustment increases the deemed royalty payment from PBI to PPC, the withholding tax analysis must be confirmed, including verification that the treaty exemption continues to apply to the increased amount.
These E&P, Subpart F, and withholding tax implications are being quantified as part of the comprehensive tax impact analysis and will be addressed in a separate memorandum.
VII. Strategic Recommendations for Formal Protest and Appeals
A. Incorporating the Correlative Adjustment Argument into the Protest
The Formal Protest, which must be filed by December 22, 2023, should include a dedicated section arguing that the $42.65 million correlative offset recognized in the NOPA is both (a) legally required by Treasury Regulation § 1.482-1(g) and (b) understated as a matter of economic analysis. Specifically, the Protest should:
(1) Establish the legal framework by citing Treas. Reg. § 1.482-1(g)(1) and (g)(2), demonstrating that correlative allocations are mandatory and that multiple § 482 adjustments must be reconciled to produce an aggregate allocation consistent with the arm's-length standard;
(2) Demonstrate the economic mechanism of overlap by walking through the interaction between the CSA adjustment and the royalty adjustment, as described in Section IV.A above, showing that both adjustments draw from the same pool of PBI income;
(3) Highlight the internal inconsistency in the IRS's positions: if the IRS's royalty adjustment is correct (i.e., the arm's-length royalty rate is 11.0%), then PBI's residual profitability is lower, which should reduce PBI's RAB share and thus its cost-sharing percentage under the CSA—partially or fully offsetting the proposed increase to that percentage. Conversely, if the IRS's CSA adjustment is correct (i.e., PBI's cost-sharing percentage should be higher, reflecting greater anticipated benefits), then PBI must be more profitable than the IRS's royalty adjustment assumes. The two positions are in tension, and the correlative offset is the mechanism for resolving that tension;
(4) Present the Whitmore Valuation Group's sensitivity analysis demonstrating that a properly computed correlative offset would reduce the net proposed adjustment by significantly more than $42.65 million, with quantified alternative offset scenarios; and
(5) Argue that the net proposed adjustment of $380.40 million exceeds the arm's-length result and should be reduced by the additional correlative offset amount identified by Whitmore, yielding a lower net adjustment.
The correlative adjustment argument should be presented as an independent ground for reducing the proposed adjustment, separate from PPC's substantive defenses on the royalty rate and CSA cost-sharing methodologies. This approach ensures that even if Appeals does not fully accept PPC's substantive positions (e.g., that the arm's-length royalty rate is 4.5% rather than 11.0%), PPC can still obtain a meaningful reduction based on the inadequacy of the correlative offset.
B. Presentation to Appeals Officer Castañeda
The correlative adjustment argument is well-suited for presentation at IRS Appeals, where the case has been assigned to Appeals Officer Noreen Castañeda. The Appeals conference is scheduled for February 28, 2024, at the IRS Appeals Office in Manhattan. The argument should be presented as follows:
(1) Frame the issue as one of internal consistency, not just taxpayer advocacy. The correlative offset is not a concession PPC is seeking; it is a correction required by the IRS's own regulations. The examination team has already recognized this by allowing the $42.65 million offset. PPC is merely arguing that the examination team did not go far enough.
(2) Demonstrate that even on the IRS's own assumptions, the net proposed adjustment overstates PPC's arm's-length income. By taking the IRS's proposed 11.0% royalty rate as a given and showing its feedback effect on the RAB calculation, PPC can demonstrate that the IRS's own positions imply a larger correlative offset—without PPC needing to concede that the 11.0% royalty rate is correct.
(3) Emphasize the hazards of litigation. If the case proceeds to the Tax Court, the IRS will face the challenge of defending two internally inconsistent positions. A Tax Court judge would likely recognize the tension between the CSA adjustment (positing a more profitable PBI) and the royalty adjustment (positing a less profitable PBI), and could reduce the aggregate adjustment accordingly. This litigation risk strengthens PPC's settlement position.
This argument is an independent ground for reducing the proposed adjustment, separate from PPC's substantive defenses on the royalty rate (CUT analysis with 14 comparables, interquartile range of 3.1% to 6.8%, median of 4.4%) and the CSA cost-sharing ratios. Presenting multiple independent grounds for reduction maximizes PPC's leverage at Appeals and increases the probability of a favorable settlement.
C. Settlement Implications
The corre

CALDERWOOD & HARKNESS LLP PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT

MEMORANDUM

Record

Parties

Dates

Amounts